DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

Stemming the tide of drug resistance in cancer

(2020) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

(2020) Giulia Bon et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression

(2019) Shreeya Kotecha et al.   Scientific Reports

Combating subclonal evolution of resistant cancer phenotypes

(2017) Samuel W. Brady et al.   Nature Communications

RAP: RNA-Seq Analysis Pipeline, a new cloud-based NGS web application

(2015) Mattia D'Antonio et al.   BMC GENOMICS

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Regulation of ERBB2 Receptor by t-DARPP Mediates Trastuzumab Resistance in Human Esophageal Adenocarcinoma

(2012) J. Hong et al.   CANCER RESEARCH

Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells

(2008) A. Belkhiri et al.   CLINICAL CANCER RESEARCH